Details

Autor(en) / Beteiligte

• Cholette, François
• Mesa, Christine
• Harris, Angela
• Ellis, Hannah
• Cachero, Karla
• Lacap, Philip
• Galipeau, Yannick
• Langlois, Marc-André
• Gingras, Anne-Claude
• Yansouni, Cedric P
• Papenburg, Jesse
• Cheng, Matthew P
• Chakraborty, Pranesh
• Stein, Derek R
• Van Caeseele, Paul
• Bartlett, Sofia
• Krajden, Mel
• Goldfarb, David
• McGeer, Allison
• Osiowy, Carla
• Hankins, Catherine
• Mazer, Bruce
• Drebot, Michael
• Kim, John
• Nasrallah, Gheyath K.

Titel

Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison

Ist Teil von

• PloS one, 2021-12, Vol.16 (12), p.e0261003-e0261003

Ort / Verlag

United States: Public Library of Science

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• The true severity of infection due to COVID-19 is under-represented because it is based on only those who are tested. Although nucleic acid amplifications tests (NAAT) are the gold standard for COVID-19 diagnostic testing, serological assays provide better population-level SARS-CoV-2 prevalence estimates. Implementing large sero-surveys present several logistical challenges within Canada due its unique geography including rural and remote communities. Dried blood spot (DBS) sampling is a practical solution but comparative performance data on SARS-CoV-2 serological tests using DBS is currently lacking. Here we present test performance data from a well-characterized SARS-CoV-2 DBS panel sent to laboratories across Canada representing 10 commercial and 2 in-house developed tests for SARS-CoV-2 antibodies. Three commercial assays identified all positive and negative DBS correctly corresponding to a sensitivity, specificity, positive predictive value, and negative predictive value of 100% (95% CI = 72.2, 100). Two in-house assays also performed equally well. In contrast, several commercial assays could not achieve a sensitivity greater than 40% or a negative predictive value greater than 60%. Our findings represent the foundation for future validation studies on DBS specimens that will play a central role in strengthening Canada's public health policy in response to COVID-19.